We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals

390 hedge funds and large institutions have $7.29B invested in Ionis Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 69 funds opening new positions, 116 increasing their positions, 131 reducing their positions, and 43 closing their positions.

New
Increased
Maintained
Reduced
Closed

60% more first-time investments, than exits

New positions opened: 69 | Existing positions closed: 43

6% more funds holding

Funds holding: 369390 (+21)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

0% less capital invested

Capital invested by funds: $7.3B → $7.29B (-$9.2M)

0.96% less ownership

Funds ownership: 86.79%85.83% (-0.96%)

11% less repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 131

13% less call options, than puts

Call options by funds: $89M | Put options by funds: $103M

Holders
390
Holders Change
+21
Holders Change %
+5.69%
% of All Funds
7.68%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.12%
New
69
Increased
116
Reduced
131
Closed
43
Calls
$89M
Puts
$103M
Net Calls
-$13.9M
Net Calls Change
-$11.1M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$1.27B +$1.46M +24,443 +0.1%
Vanguard Group
2
Vanguard Group
Pennsylvania
$723M -$14.8M -248,083 -2%
Baillie Gifford & Co
3
Baillie Gifford & Co
United Kingdom
$531M +$22.3M +374,736 +4%
BG
4
Bellevue Group
Switzerland
$509M +$6.55M +109,906 +1%
BlackRock
5
BlackRock
New York
$508M +$3.07M +51,590 +0.6%
ClearBridge Investments
6
ClearBridge Investments
New York
$484M -$80M -1,343,348 -14%
Wellington Management Group
7
Wellington Management Group
Massachusetts
$407M -$60M -1,007,483 -13%
State Street
8
State Street
Massachusetts
$232M +$11.7M +196,602 +5%
Invesco
9
Invesco
Georgia
$142M -$1.29M -21,637 -0.9%
WRF
10
Waddell & Reed Financial
Kansas
$132M -$59M -989,941 -31%
BI
11
BVF Inc
California
$132M +$74.1M +1,244,187 +133%
Renaissance Technologies
12
Renaissance Technologies
New York
$123M +$13.4M +225,700 +12%
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$113M -$5.09M -85,428 -4%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$87.1M +$936K +15,705 +1%
American Century Companies
15
American Century Companies
Missouri
$85.6M +$2.65M +44,471 +3%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$82.6M -$14.8M -247,600 -15%
Norges Bank
17
Norges Bank
Norway
$73M -$11.1M -186,410 -13%
Wells Fargo
18
Wells Fargo
California
$62.1M -$767K -12,876 -1%
First Trust Advisors
19
First Trust Advisors
Illinois
$60.4M +$605K +10,162 +1%
Sumitomo Mitsui Trust Group
20
Sumitomo Mitsui Trust Group
Japan
$58.6M +$6.24M +104,720 +12%
Northern Trust
21
Northern Trust
Illinois
$48.2M -$57.9K -971 -0.1%
Bank of America
22
Bank of America
North Carolina
$46.2M -$3.87M -64,887 -8%
RJA
23
Raymond James & Associates
Florida
$42.5M -$1.78M -29,830 -4%
PA
24
Pinnacle Associates
New York
$42.4M -$3.9M -65,401 -9%
DY
25
Dowling & Yahnke
California
$40.8M

IONS Hedge Fund Activity: Q4 2019 in Review

390 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q4 2019, worth a combined $7.29B — down 0.13% from $7.3B a quarter earlier.

Buyers outnumbered sellers: 69 funds opened new IONS positions and 43 closed out — a net gain of 26 holders — while 116 added to existing stakes and 131 trimmed.

The largest buyer was BVF Inc, adding an estimated $74.1M. The largest seller was ClearBridge Investments, cutting an estimated $80M.

  • 390 institutional investors held Ionis Pharmaceuticals (IONS) as of Q4 2019, up from 369 in Q3 2019.
  • Funds reported $7.29B of Ionis Pharmaceuticals stock for Q4 2019, down 0.13% quarter-over-quarter.
  • 69 funds opened new Ionis Pharmaceuticals positions in Q4 2019 and 43 closed out, a net change of +26 holders.
  • The largest Ionis Pharmaceuticals buyer in Q4 2019 was BVF Inc, an estimated $74.1M added.
  • The largest Ionis Pharmaceuticals seller in Q4 2019 was ClearBridge Investments, an estimated $80M sold.

Based on aggregated 13F filings for Q4 2019.